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CAPSULE SUMMARY 
• Voriconazole exposure and longer duration of voriconazole were found to be 
significantly associated with increased risk of squamous cell carcinoma. 
• Regular dermatologic surveillance should be considered for the patients taking 
voriconazole, especially those at high risk of developing squamous cell carcinoma.  
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ABSTRACT 
Background: Current evidence about the association between voriconazole and risk of 
cutaneous squamous cell carcinoma (SCC) remains inconsistent.  
Objective: To assess the association between voriconazole use and risk of SCC.  
Methods: We systematically searched PubMed and Embase and performed a random 
effects model meta-analysis to calculate the pooled relative risk (RR) with 95% 
confidence interval (CI).  
Results: Of the 8 studies involving 3,710 individuals with lung transplant (LT) or 
hematopoietic cell transplant (HCT) included in qualitative analysis, five studies were 
included in the meta-analysis. Use of voriconazole was significantly associated with 
increased risk of SCC (RR, 1.86; 95% CI, 1.36 – 2.55). The increased risk did not differ 
according to type of transplantation or adjustment for sun exposure. Longer duration of 
voriconazole was found to be positively associated with risk of SCC (RR, 1.72; 95% CI, 
1.09 – 2.72). Voriconazole use was not associated with increased risk of basal cell 
carcinoma (RR, 0.84; 95% CI, 0.41 – 1.71).  
Limitations: There were some heterogeneities in retrospective observational studies. 
Conclusions: Our findings support an increased risk of SCC associated with 
voriconazole in individuals with LT or HCT. Routine dermatologic surveillance should be 
performed, especially among individuals at high risk of developing SCC.  
Key words: voriconazole; squamous cell carcinoma; me; meta-analysis 
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INTRODUCTION 
   Non-melanoma skin cancer (NMSC) is the most common malignancy among 
individuals with solid organ transplantation 1 or hematopoietic cell transplantation 
(HCT).2, 3 The most common NMSC among this population is cutaneous squamous cell 
carcinoma (SCC), followed by basal cell carcinoma (BCC),1 which together account for 
95% of skin cancers in organ transplant recipients.4 Individuals after solid organ 
transplantation had a higher risk for NMSC compared to the general population,5, 6 and 
this risk increased with time after transplantation.7 Moreover, NMSC appears to be more 
aggressive among solid organ transplant recipients than in the general populations, 
which increases mortality among solid organ recipients.8, 9 Several risk factors, including 
history of frequent sun exposure, male sex, Fitzpatrick skin type I to III, older age at 
transplantation, immunotherapies, and underlying disease were found to be associated 
with increased risk of NMSC post-transplantation.10-14 
   Since 2002, voriconazole has been used to manage or prevent fungal infections, 
which are important complications after LT or HCT and can result in significant morbidity 
and mortality.15, 16 However, voriconazole can cause significant toxicity and side effects, 
including hepatotoxicity, visual disturbances, and photosensitivity.17 Recently, the 
increased risk of NMSC (primarily SCC) associated with voriconazole use attracted our 
attention. Voriconazole and its major hepatic metabolite, voriconazole N-oxide (VNO) 
may generate reactive oxygen species and induce DNA damage by sensitizing 
keratinocytes to ultraviolet (UV) A light.18 However, current evidence regarding the 
association between use of voriconazole and risk of SCC among the patients with LT 
and HCT remains controversial.7, 19-26 The conflicting results might be due to small 
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sample size in individual studies, heterogeneity in populations, duration or dose of 
voriconazole, or the use of combination treatments. We, therefore, conducted this 
systematic review and meta-analysis of available observational studies to critically 
analyze and synthesize the evidence regarding the association between use of 
voriconazole and risk of SCC or BCC following LT and HCT.  
MATERIALS AND METHODS 
   The study was performed in accordance with the Meta-analysis Of Observational 
Studies in Epidemiology (MOOSE) guidelines for reviews of observational studies.27 
Search strategy and study selection  
   PubMed and Embase were searched from inception to September 2017 to identify 
eligible observational studies (Supplemental Table 1). Additionally, we searched the 
reference lists of relevant review and included studies. Two reviewers (HT and WS) 
selected the studies that met the following criteria: 1) observational (both prospective 
and retrospective) studies; 2) evaluating the association between voriconazole and risk 
of SCC or BCC; and 3) reporting the outcome of SCC or BCC. We included the latest 
study only in case of multiple reports using the same database. Conference abstracts 
were excluded because they offered limited information on study quality, population, and 
outcomes. 
Data extraction and quality assessment  
   We collected information on study design, data source, number of participants, age 
(years), selection criteria, exposure definition, adjusted covariates, and outcomes of 
interest. Estimates on risk of SCC or BCC were extracted if appropriate. The quality of 
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the observational study was assessed using a 9-star scoring system as described by 
Newcastle-Ottawa quality-assessment scale (NOS), with total stars of 7 - 9 and 5 - 6 
indicating high and moderate quality, respectively.28 Two reviewers (HT and WS) 
independently extracted the data and assessed the quality of each study. We contacted 
the original author for more information if any missing information. Any disagreement 
was resolved by consensus or referral to a third reviewer (JH).  
Statistical analysis  
  To account for heterogeneity between studies, a random-effects model was used to 
calculate the pooled relative risk (RR) and 95% confidence interval (CI) for the 
association between voriconazole exposure and risk of SCC or BCC. Statistical 
heterogeneity was quantified using the I² statistic (low heterogeneity: 25%, moderate 
heterogeneity: 50%, and high heterogeneity: 75%).29 Subgroup analysis by type of 
transplantation or adjustment for sun/SUV exposure was performed to assess the 
consistency of the association between voriconazole and SCC risk. A sensitivity analysis 
was performed by removing one study at a time from the pooled analysis to evaluate its 
influence on the pooled estimate. The development of the evidence on the association 
between voriconazole and risk of SCC was tested by using a cumulative meta-analysis 
based on the date of publication. A visual inspection of the funnel plots and the Begg’s 
and Egger’s tests were applied to examine potential publication bias. All statistical 
analyses were performed with STATA (Version 14; Stata Corp., College Station, TX). 
RESULTS 
Study selection and study characteristics 
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  Of 294 citations retrieved from electronic databases, eight observational studies 
involving 3,710 individuals met the eligibility criteria and were included in our systematic 
review (Fig 1). Two studies used the same database,21, 22 thus we included the latest 
study only.22 Of the eight studies included, seven were retrospective cohort studies and 
one was a retrospective case-control study. The characteristics and main results of the 
included studies are presented in Table 1 and Supplemental Table 2, respectively. 
Four studies were assessed as high quality,20, 22, 24, 25 and the remaining four studies 
were determined to be of moderate quality.7, 19, 23, 26 (Supplemental Table 3) Six studies 
providing adequate data on the risk of SCC or BCC associated with voriconazole were 
included in the meta-analysis. 
SCC risk 
   Eight studies involving 3,710 patients assessed the relationship between 
voriconazole exposure and risk of SCC.7, 19, 20, 22-26 Six studies were performed in 
individuals with LT 7, 20, 22, 24-26 and two studies were performed in those with HCT.19, 23 A 
total of 405 SCC cases were identified among these patients, with a crude incidence of 
10.9%. However, only five studies (3,122 patients with 272 SCC cases) provided 
relevant data on risk of SCC and were included in the meta-analysis.7, 19, 22, 23, 25 The 
overall RR for SCC risk associated with voriconazole was 1.86 (95% CI, 1.36 – 2.55), 
with low heterogeneity across studies (I2 = 4.5%) (Fig 2). Subgroup analysis by 
transplantation type showed a higher risk of SCC associated with voriconazole in both 
LT recipients (RR, 1.65; 95% CI, 1.02 – 2.68) and HCT recipients (RR, 2.29; 95% CI, 
1.37 – 3.82) (Supplemental Fig 1). Significantly increased risk of SCC was associated 
with voriconazole, regardless of whether a study adjusted for sun/UV exposure (adjusted 
9  
  
RR: 2.42; 95% CI 1.38 – 4.22; unadjusted RR: 1.64; 95% CI 1.04 – 2.58) (Supplemental 
Fig 2). 
   The significant association between voriconazole and increased risk of SCC 
remained robust in the sensitivity analysis when each study was removed from 
meta-analysis at a time (Supplemental Fig 3). Our cumulative meta-analysis ordered by 
publication year indicated that the association became significant since 2017 
(Supplemental Fig 4). There was no evidence of substantial publication bias based on 
the Egger’s test (P = 0.98), Begg’s test (P = 0.81), or visual inspection of the funnel plot 
(Supplemental Fig 5). 
Dose- and duration- response analyses 
   Six studies evaluated the relationship between duration of voriconazole therapy and 
risk of SCC.7, 19-21, 25, 26 (Supplemental Table 2) Five studies found that voriconazole 
duration was significantly associated with the development of SCC 19-21, 25, 26, while one 
study found no such association.7 Meta-analysis of four studies found that longer 
duration of voriconazole was significantly associated with increased risk of SCC (RR, 
1.72; 95% CI, 1.09 – 2.72),7, 19, 25, 26 while a non-significant positive association was 
observed in cumulative days of voriconazole use (RR, 1.74 per 180 days; 95% CI, 0.95 – 
3.18) (Supplemental Fig 6). In addition, two studies evaluating cumulative dose and risk 
of SCC reported a statistically significant dose-response relationship (Supplemental 
Table 2).22, 25  
BCC risk  
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   Two studies involving 41 BCC cases among 1,386 patients (crude incidence: 3.0 %) 
were included in the meta-analysis.7, 23 Neither found any association between 
voriconazole use and risk of BCC. The overall RR was 0.84 (95% CI, 0.41 – 1.71) (Fig 
2). 
DISCUSSION 
   Our meta-analysis of observational studies found that voriconazole use was 
significantly associated with increased risk of SCC in both LT recipients and HCT 
recipients. Our sensitivity analysis omitting each study, one at a time, confirmed the 
robustness of our results. Cumulative meta-analysis indicated that the significant 
increase in the risk of SCC associated with voriconazole became robust beginning in 
2017. Furthermore, longer duration or higher dose of voriconazole was associated with 
increased risk of SCC. However, there was no significant association between 
voriconazole exposure and risk of BCC.  
   Consistent with most previous studies, 19, 20, 22-26 our results found that voriconazole 
use was significantly associated with increased risk of SCC. Although the potential 
carcinogenic mechanisms by which voriconazole cause SCC have not been fully 
elucidated, it has been hypothesized that either voriconazole or VNO may facilitate 
UV-induced DNA damage and inhibit DNA repair.18, 30 Furthermore, VNO may cause 
phototoxicity through non-radiation related mechanisms after exposure to UVB.31-33 
Since cytochrome P450 enzymes are expressed not only in the liver but also in human 
keratinocytes,34 an accumulation of VNO in the skin may explain our findings that longer 
duration and higher dose of voriconazole were independent risks for SCC.18 Sun 
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exposure is more strongly related to the risk of SCC than BCC.35 Photosensitizing 
medications (e.g., diuretics) were found to be more strongly associated with SCC than 
BCC.36 Therefore, it was not surprising that our study found no association between 
voriconazole and BCC, though this might also be falsely negative due to the inclusion of 
only two studies. In addition, it should be noted that we observed a significant increase in 
the risk of SCC, regardless of whether a study adjusted for sun exposure. Thus, 
phototoxicity may not be the sole carcinogenic pathway involved. Some studies have 
found that voriconazole may promote tumor development by upregulating aryl 
hydrocarbon receptor-dependent COX pathway,33 and induce SCC by regulating distinct 
cell cycle and terminal differentiation pathways in human keratinocytes.32   
   Our study systematically searched all available cohort or case-control 
studies on voriconazole use and risk of SCC or BCC without any restriction 
(e.g., language). Moreover, we fully assessed the methodological quality of the 
included studies and provided separate outcomes for SCC and BCC. Finally, 
subgroup analysis, sensitivity analysis, cumulative meta-analysis, and 
dose-response analysis were performed to test the robustness of our findings.  
Our meta-analysis had several limitations. First, the definition of voriconazole 
treatment varied considerably among studies, ranging from ever-exposure to at 
least 3 consecutive months of voriconazole therapy, which was undefined in 
many studies. Additionally, voriconazole was commonly used in combination 
with immunosuppressants in both LT recipients and HCT recipients. 
Immunosuppressants, especially azathioprine, were considered a strong risk 
factor for SCC.37, 38 However, several studies did not provide details of 
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treatment combinations so that we could not address this issue in our study. 
One study adjusted for immunosuppression regimen, mean cyclosporine level, 
and mean tacrolimus level, found a significant increase in the risk of SCC.25   
One included study found no association between any particular 
immunosuppressive medication and risk of skin cancer.7 Further studies are 
clearly warranted to explore potential interaction between voriconazole and 
immunosuppressive therapies on skin cancer among those patients with LT or 
HCT. Finally, some clinical factors, such as time since transplantation,39 age at 
transplantation, skin type, and history of NMSC, might confound the relation 
between voriconazole and SCC. However, we cannot further eliminate residual 
confounders due to the limited number of studies included and the lack of 
information provided.         
   In summary, our systematic review and meta-analysis of 8 observational 
studies suggested a significant association between voriconazole use and 
increased risk of SCC among individuals who have undergone LT or HCT. A 
trend to a dose- and duration-response relationship was noted. The findings 
support the need for regular dermatologic surveillance for the patients taking 
voriconazole and also suggest taking the alternatives to voriconazole (e.g., 
posaconazole), especially among those already at elevated risk of SCC. Given 
relatively limited data, further large, high-quality studies with more detailed 
exposure information in terms of dose and duration of voriconazole and 
adequate adjustment for potential confounders (e.g., UV exposure) are required 
for confirmation of our findings. 
13  
  
Abbreviations used: 
BCC: basal cell carcinoma 
CI: confidence interval 
HCT: hematopoietic cell transplantation 
NMSC: non-melanoma skin cancer 
NOS: Newcastle-Ottawa quality-assessment  
RR: relative risk 
SCC: squamous cell carcinoma 
UV: ultraviolet 
VNO: voriconazole N-oxide 
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Table 1. Characteristics of included studies 
 
Study Design and data 
source 
No. of 
participants 
Age (years) Selection 
criteria 
Exposure definition Adjusted covariates 
Vadnerkar 
et al., 
2010 20 
Retrospective, 
case–control study; 
University of Pittsburgh 
Medical Center 
(UPMC) between 2003 
and 2008;  
Median follow-up: 36 
months 
68 LTs; 
SCC cases: 
n=17, 
Control: n=51 
Median:  
Cases: 63; 
Control: 56 
Patients with LT 
or heart–lung 
transplantation 
Cumulative doses and 
total durations of 
voriconazole use obtained 
from the UPMC pharmacy 
record and Cardiothoracic 
Transplant database, 
respectively 
Greater age at the 
time of transplant, 
male gender, 
residence in a 
location with high 
levels of sun 
exposure, single-lung 
transplant and 
duration and 
cumulative dose of 
voriconazole 
Feist et 
al., 2012 
26 
Retrospective cohort 
study;  
University of California 
San Diego Health 
System between 2000 
and 2006; 
Follow-up: NR 
120 LTs; 
Voriconazole: 43 
No voriconazole: 
77; 
SCC cases:32 
Mean: 
Voriconazole: 
49.4; 
No voriconazole: 
48.6 
Single or 
bilateral 
sequential single 
(double) LTs 
Exposed to voriconazole  NR 
Rashtak 
et al., 
2015 7 
Retrospective cohort 
study;  
Mayo Clinic between 
1990 and 2011; 
Median follow-up: 3 
years 
166 LTs; 
SCC cases: 44, 
BCC cases: 19  
Mean: 52 LT alone,  
heart- lung 
transplantation, 
or lung-heart- 
liver 
transplantation 
NR Univariate Cox 
models 
Wojenski 
et al., 
2015 19 
Retrospective cohort 
study;  
Mayo Clinic from 2007 
to 2012;  
Follow-up: NR 
381 HSCT 
patients; 
SCC cases: 27 
Median: 53 Adult patients 
with allogeneic 
HSCT 
Intravenous or oral 
voriconazole use at any 
time during treatment of 
their hematologic disease, 
before or after HSCT 
Male gender; 
Transplant age; TBI 
conditioning; Skin 
cancer pre-HSCT; 
Chronic GVHD; 
photopheresis; UV 
therapy 
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Kolaitis et 
al., 2016 
24 
 
Retrospective cohort 
study;  
University of California 
at Los Angeles 
between 2005 and 
2012;  
Follow-up: NR 
400 LTs; 
SCC cases: 84 
Mean: 59  Adult recipients 
of a first single or 
bilateral LT 
Exposure to fungal 
prophylaxis was measured 
in two ways: (i) targeted 
and universal prophylaxis 
groups and (ii) cumulative 
time-dependent 
exposure to specific 
medications 
Patients’ age 
at transplant, gender, 
race, diagnosis, 
transplant type, and 
time-dependent 
cumulative AR score 
Mansh et 
al., 2016 
22 
Retrospective cohort 
study;  
University of California 
at San Francisco 
between 1991 and 
2012;  
Follow-up: NR 
455 LTs; 
SCC cases: 86 
Median: 55.4 Single lung, 
double lung, or 
heart-lung 
transplantation 
Exposed to voriconazole 
identified using medical 
record review 
Sex, race (White vs. 
Non-White) and age 
at transplant 
Hamandi 
et al.,2017 
25 
Retrospective, cohort 
study; 
14 LT centers across 9 
countries during 
2005-2008;  
Median follow-up: 3.51 
years 
900 LTs; 
SCC cases: 55 
Median:53 Adult patients 
who underwent 
single LT, double 
LT, or heart-lung 
transplantation 
Cumulative voriconazole 
exposure of ≥ 30 days, not 
necessarily consecutive 
Age, sex, 
immunosuppression 
regimen, mean 
cyclosporine 
level, mean 
tacrolimus level, sun 
exposure, history of 
malignancy 
pretransplantation, 
transplant rejection 
episodes, and 
underlying disease. 
Kuklinski 
et al., 
2017 23 
Retrospective cohort 
study;  
Stanford Blood 
and Marrow 
Transplantation 
database between 
2003 to 2015; 
follow-up: NR 
1220 allogeneic 
HCTs; 
SCC cases: 60; 
BCC cases: 22 
Mean:49.2 allogeneic HCT Use of voriconazole either 
before or after HCT 
Older age at the time 
of HCT, male sex, 
white race, and 
history of NMSC; 
Chronic GVHD  
HCT, hematopoietic cell transplant; HSCT, hematopoietic stem cell transplant; LT, lung transplant; NR, not reported; GVHD, 
graft-versus-host disease; COPD, chronic obstructive pulmonary disease; UV, ultraviolet 
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Figure legends:   
Fig 1. Flow chart of the identification of eligible studies. SCC, squamous cell carcinoma; 
BCC, basal cell carcinoma.  
Fig 2. Meta-analysis of the association between voriconazole use and risk of squamous 
cell carcinoma and basal cell carcinoma. 
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Figure 1. 
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Figure 2. 
 
 
